Original BioMedicals Co., Ltd. (6483)
TWSE TWSE Primary Summary
Original BioMedicals Co., Ltd. (6483) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Original BioMedicals Co., Ltd. ever had a stock split?
Original BioMedicals Co., Ltd. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | - CEO | TWSE Exchange | TW0006483001 ISIN |
| Taiwan Country | 20 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Original BioMedicals Co., Ltd. is a pioneering biotechnology company based in Taipei, Taiwan, committed to developing innovative chemical entities designed to address unmet medical needs. Since its establishment in 2011, the company has been focused on creating solutions that mitigate the harmful effects of radiation exposure and improve the treatment of type 2 diabetes. Through its dedication to science and innovation, Original BioMedicals Co., Ltd. aims to enhance patient care and provide effective treatments for various medical conditions.
Products and Services
- (A01) Radprotect
- (A02) CCM-Ami
- ((P01) GLP-1 CCM
A pre-clinical product currently under development, Radprotect is designed to offer protection against radiation exposure. This innovative solution aims to mitigate the harmful effects of radiation, providing a safeguard for individuals at risk of exposure in medical, industrial, or emergency situations.
CCM-Ami represents a groundbreaking approach to protect normal tissues from the toxic effects of chemotherapeutic agents and ionizing radiation. This product is being developed to minimize the collateral damage often associated with cancer treatments, thereby improving the quality of life for patients undergoing chemotherapy and radiotherapy.
Targeting the management of type 2 diabetes, ((P01) GLP-1 CCM is a therapeutic solution in development aimed at enhancing the treatment options for this prevalent chronic disease. Through the modulation of GLP-1 activity, this product seeks to offer better control of blood sugar levels, promising an improved standard of care for patients with type 2 diabetes.
